Technology
Jul 11, 2024, 1:44 PM
Jul 11, 2024, 12:00 AM
ABC NewsUPI

Pfizer is working on a modified version of its weight-loss drug

Pfizer American multinational pharmaceutical corporation
Independent
/
Source
Pfizer CEO Plans Shift to Cancer and Obesity Treatments

Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world

ABC News
/
Source
Pfizer CEO Plans Shift to Cancer and Obesity Treatments

Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world

Associated Press
/
Source
Pfizer CEO Plans to Shift Focus from COVID to Cancer and Obesity Treatments

Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world.

ABC News
/
Source
Pfizer CEO Plans Shift to Cancer and Obesity Treatments

Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world

ABC News
/
Source
Pfizer targets obesity with new once-daily danuglipron drug

Pfizer announced that it has selected its preferred once-daily modified release formulation of danuglipron, a move that is significant in the obesity drug’s development.

UPI
/
Source
Pfizer commits to modified version of its weight-loss drug danuglipron - UPI.com

Pfizer Inc. announced on Thursday that it will move forward with the testing of its modified version of the once-daily weight loss drug danuglipron.

Opinions

You've reached the end